source
- Claris Biotherapeutics raises $118M Series B to advance corneal stem-cell eye dropClaris Biotherapeutics announced a $118 million Series B financing round led by Novo Holdings and supported by several venture firms. The funding will be used to move its lead candidate, CSB-001, i…
- RA Capital backs Oak Hill Bio's Nasdaq debut via $175 million SPAC mergerRA Capital announced that its SPAC, Research Alliance Corporation III, will merge with Oak Hill Bio, creating a new Nasdaq-listed rare-disease company. The combined entity will start with $175 mil…